证券代码：601998 证券简称：中信银行 公告编号：临2025-085 中信银行股份有限公司董事会会议决议公告 表决结果：赞成10票 反对0票 弃权0票 二、审议通过《关于预期信用损失法实施相关事项的议案》 表决结果：赞成10票 反对0票 弃权0票 三、审议通过《关于修订〈中信银行资本管理办法〉的议案》 表决结果：赞成10票 反对0票 弃权0票 四、审议通过《中信银行2026年董事会对董事长授权方案》 方合英董事长因与该议案存在利害关系，回避表决，亦不代理芦苇董事行使表决权，该议案有效表决票 数为8票。 本行董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 中信银行股份有限公司（以下简称本行）于2025年12月10日以书面形式发出有关会议通知和材料，于 2025年12月24日在北京市朝阳区光华路10号院1号楼中信大厦以现场会议形式完成一次董事会会议召开 并形成决议。本次会议应出席董事10名，实际出席董事10名，其中，芦苇执行董事因公务委托方合英董 事长代为出席并表决，廖子彬董事以视频方式参加会议。本次会议由方合英董事长主持，本行高级 ...

Group 1: Share Buyback Announcement - The company approved a share buyback plan at the shareholder meetings held on December 24, 2024, and May 29, 2025, with a total amount not less than RMB 60 million and not exceeding RMB 100 million, at a price not exceeding RMB 45.00 per share [2][3] - As of December 23, 2025, the company completed the buyback of 16,193,259 A-shares, accounting for 1.79% of the total share capital, with a total expenditure of RMB 600,217,787.75 [3][4] - The repurchased shares will be fully canceled, leading to a reduction in registered capital, and the company will submit the cancellation application to the relevant authorities [3][6] Group 2: Compliance and Implementation - The buyback process complied with relevant regulations, and the total funds used, repurchase price, and number of shares repurchased were consistent with the approved plan [5][6] - The company did not engage in stock trading during sensitive periods, ensuring compliance with trading regulations [10][11] Group 3: New Drug Application - The company’s subsidiary received a notice from the National Medical Products Administration regarding the acceptance of the registration application for "Lai Kang Qi Ta Monoclonal Antibody Injection" [16][17] - This drug is a first-in-class IL-17A/F dual-target inhibitor for treating moderate to severe plaque psoriasis, with promising clinical trial results showing superior efficacy compared to the control group [18][20] - The total R&D investment for this drug has reached approximately RMB 20.4 million, and there are currently no approved products for the same indication in the domestic market [20]

Core Viewpoint - Chongqing Zhixin Industrial Co., Ltd. is set to conduct its initial public offering (IPO) and list on the main board, following approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][17]. Group 1: Issuance Details - The company plans to issue a total of 56,666,667 shares, representing 25% of the total share capital post-issuance, with no existing shares being transferred [19]. - The issuance will combine strategic placement, offline issuance, and online issuance, with the lead underwriters responsible for organizing these processes [17][20]. - The initial strategic placement will consist of 11,333,333 shares, accounting for 20% of the total issuance, while the offline and online offerings will be 27,200,334 shares and 18,133,000 shares, respectively [20]. Group 2: Pricing Mechanism - The issuance price will be determined through preliminary inquiries from qualified investors, without cumulative bidding [21]. - The pricing will consider various factors, including the company's profitability, growth potential, and comparable company valuations, while excluding the highest bids [11][21]. - Investors must submit their pricing basis and suggested price ranges during the inquiry period, with specific requirements for institutional and individual investors [5][6]. Group 3: Investor Participation - Qualified offline investors include registered securities firms, fund management companies, and other institutional investors, as well as individual investors [3][4]. - Investors must complete registration and submit necessary documentation by December 29, 2025, to participate in the offline issuance [3][4]. - The maximum subscription amount for each investor is capped at 13.6 million shares, which is 50% of the initial offline issuance [10]. Group 4: Lock-up Period - For the offline issuance, 10% of the allocated shares will be subject to a six-month lock-up period, while 90% will be freely tradable upon listing [13][22]. - The online issuance shares will have no lock-up restrictions and will be tradable immediately after listing [22]. Group 5: Important Dates - The roadshow for offline investors will take place from December 25 to December 29, 2025, with an online roadshow scheduled for January 5, 2026 [26].

Group 1 - The company held its fourth temporary board meeting on December 23, 2025, to discuss various proposals [2][3] - The board approved the proposal for estimated daily related transactions for 2026, which will be submitted to the shareholders' meeting for review [3][4] - The board also approved a credit limit application of up to RMB 1.2 billion for 2026, which can be used for various financing activities [7][9] - A proposal to use up to RMB 600 million of idle funds for cash management was approved, allowing for investment in low-risk financial products [11][45] - The board approved an organizational structure adjustment to enhance management efficiency [14][15] - A proposal to hold the first temporary shareholders' meeting of 2026 on January 9, 2026, was also approved [16][17] Group 2 - The company plans to submit the estimated daily related transactions for 2026 to the shareholders' meeting, emphasizing that these transactions are necessary for normal operations and will not harm the company's interests [51][52] - The estimated daily related transactions for 2026 include transactions with related parties such as Guangzhou Sichuang Technology Co., Ltd. and Jiangxi Kaima Bailujia Bus Co., Ltd. [55][61] - The company has a history of cooperation with related parties, ensuring that transactions are fair and do not affect the company's independence [78][79]

Group 1 - The company approved the transfer of 9.68% equity stake in Guangdong Provincial Highway Development Co., Ltd. (粤高速A) by its wholly-owned subsidiary, Shandong High-speed Investment Development Co., Ltd. (投资公司), at a price of 12.03 yuan per share, totaling 2.435 billion yuan [2] - The board meeting held on November 28, 2025, authorized the management to handle the share transfer, and the decision was ratified in the fourth extraordinary shareholders' meeting on December 15, 2025 [2] - The share transfer was completed on December 24, 2025, with the relevant share transfer registration procedures finalized, resulting in the investment company no longer holding any shares in粤高速A [3]

Group 1 - The company held its 20th meeting of the 9th Board of Directors on December 23, 2025, with all 9 directors present, and the meeting was conducted in accordance with relevant laws and regulations [2][3] - The Board approved several proposals, including the change of the accounting firm, with 100% approval from the attending directors [3][10] - The proposal to change the accounting firm requires further approval from the shareholders' meeting [5][60] Group 2 - The company proposed to extend a loan of 12 million yuan from its controlling shareholder, with a maximum extension period of 10 months at an annual interest rate of 6.9%, without requiring collateral [44][47] - This loan extension constitutes a related party transaction and requires approval from the shareholders' meeting, with related shareholders abstaining from voting [45][53] - The company has previously engaged in related transactions with its controlling shareholder, including loans and other financial arrangements [48][50] Group 3 - The company’s subsidiary, Weifang Yaxing New Materials Co., Ltd., is transferring 7.1438% of its equity for 60 million yuan, with the company waiving its right of first refusal [28][29] - This transaction does not constitute a related party transaction or a major asset restructuring and will not affect the company's financial status significantly [40][30] - The transaction is part of the company's strategic adjustments and does not change its ownership structure in the subsidiary [40][29] Group 4 - The company plans to hold its first extraordinary shareholders' meeting of 2026 on January 9, 2026, with both on-site and online voting options available [14][15] - The meeting will address the proposals approved by the Board, including the change of accounting firm and the loan extension [17][18] - Shareholders must register to attend the meeting and can delegate their voting rights to a proxy [20][22] Group 5 - The company intends to change its accounting firm to Zhongshun Zhonghuan Accounting Firm, which has a strong reputation and experience in auditing public companies [59][61] - The previous accounting firm, Yongtuo, has no objections to the change, and the transition will be managed according to regulatory requirements [72][73] - The new accounting firm is expected to enhance the company's financial audit processes and internal controls [61][72]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601168 证券简称：西部矿业 公告编号：临2025-058 西部矿业股份有限公司 关于选举第八届董事会职工董事的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 根据《公司法》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第1号一一 规范运作》等法律法规、规范性文件及《公司章程》的相关规定，公司董事会由7名董事组成，其中独 立董事3名，非独立董事3名，职工董事1名。公司于2025年12月24日召开了2025年第8次工会委员会，选 举胡惠杰先生为公司第八届董事会职工董事，任期自本次工会委员会审议通过之日起至第八届董事会届 满为止。 上述职工董事符合《公司法》等相关法律法规及规范性文件有关董事任职的资格和条件。公司第八届董 事会中兼任公司高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一。 特此公告。 西部矿业股份有限公司 董事会 2025年12月25日 证券代码：601168 证券简称：西部矿业 公告编号：临2 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025年12月24日 2、董事会秘书列席会议，部分公司高管列席。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于公司2025年中期利润分配的议案 审议结果：通过 (二)股东会召开的地点：中国化学大厦 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，由公司董事长莫鼎革先生主持。会议的召集、召开及表决方式符合《公司 法》等法律法规及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席7人； 表决情况： ■ 2、议案名称：关于公司回购注销部分限制性股票及调整回购价格的议案 审议结果：通过 表决情况： ■ (二)现金分红分段表决情况 ■ (三)涉及重大事项，5%以下股东的表决情况 本次股东会表决方式符合《公司法》及《公司章程 ...

Drug Information - The drug "Lai Kang Qi Ta" monoclonal antibody injection has received acceptance for domestic production registration from the National Medical Products Administration (NMPA) [1] - It is classified as a Class 1 therapeutic biological product and is intended for adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy [1] - The drug is a self-developed innovative IL-17A/F dual-target inhibitor, which is the first of its kind in China and the second globally [1][2] Clinical Development - A clinical trial for the drug is set to achieve primary and secondary efficacy endpoints by July 2025, demonstrating superior efficacy compared to the control group [1] - The trial results indicate faster onset, better short-term efficacy, long-lasting effects, and less frequent dosing compared to the control drug [1] - The cumulative R&D investment for the drug is approximately RMB 204.03 million [2] Market Situation - As of the announcement date, there are no approved products in China for psoriasis indications targeting the IL-17A/F dual-target [3] - There are three imported and two domestic products approved for IL-17A and IL-17RA single-target indications [3] - The estimated domestic terminal sales for IL-17A and IL-17RA single-target drugs in 2024 is RMB 2.833 billion [3]

Core Viewpoint - The company has issued convertible bonds totaling RMB 29,532.80 million, with a six-year term and a tiered interest rate structure, which will mature on December 24, 2025 [2]. Group 1: Convertible Bond Issuance - The company issued 2,953,280 convertible bonds at a face value of RMB 100 each, approved by the China Securities Regulatory Commission [2]. - The interest rates for the bonds are structured as follows: 0.40% for the first year, 0.60% for the second year, 1.00% for the third year, 1.50% for the fourth year, 1.80% for the fifth year, and 2.00% for the sixth year [2]. Group 2: Redemption and Conversion Details - The redemption date for the bonds is set for December 23, 2025, with a total redemption amount of RMB 112 per bond, including the final interest payment [3]. - As of December 23, 2025, a total of RMB 293,768,000 worth of bonds have been converted into 94,689,715 shares, representing 7.10% of the company's total share capital prior to conversion [3][6]. Group 3: Impact on Share Capital - From October 1, 2025, to December 23, 2025, RMB 188,542,000 worth of bonds were converted into 60,819,321 shares, leading to a dilution of existing shareholders' equity [4][7]. - The total share capital increased to 1,924,470,671 shares as a result of the conversions, with the controlling shareholder's stake diluted from 30.07% to 29.12% [7][8]. Group 4: Major Shareholder Changes - The major shareholders, including the controlling shareholder, did not change their total number of shares held, but their ownership percentages were diluted due to the bond conversions [8].